HyStem-HP for Drug Delivery
11/03/20
Publication Title:
Weekly Injection of IL-2 Using an Injectable Hydrogel Reduces Autoimmune Diabetes Incidence in NOD Mice.
Advanced BioMatrix Products Used:
HyStem-HP - Thiolated Hyaluronic Acid Kit
Advanced BioMatrix HyStem eBrochure
How the products were used:
HyStem-HP was used as an injectable to deliver IL-2 as a therapy for autoimmune type I diabetes. The thiolated heparin in the HyStem-HP kit helps control the drug release due to the IL-2 binding capabilities of Heparin.
Article Abstract:
IL-2 injections are a promising therapy for autoimmune type 1 diabetes but the short half-life of this cytokine in vivo limits effective tissue exposure and necessitates frequent injections. Here we have investigated whether an injectable hydrogel could be used to promote prolonged IL-2 release in vivo. Methods Capitalising on the IL-2-binding capabilities of heparin, an injectable hydrogel incorporating clinical-grade heparin, collagen and hyaluronan polymers was used to deliver IL-2. The IL-2-release kinetics and in vivo stability of this material were examined. The ability of soluble IL-2 vs hydrogel-mediated IL-2 injections to prevent autoimmune diabetes in the NOD mouse model of type 1 diabetes were compared.
Link to the publication:
https://link.springer.com/article/10.1007/s00125-020-05314-1
